ASH News Daily 2013 - Day 2 - (Page B-5)
ASH News Daily
Sunday, December 8, 2013
Page B-5
®
ASH Honors Trainees with Outstanding Abstract
Achievement Awards for Top-Scoring Abstracts
T
he American Society of
Hematology is pleased to recognize the following abstract
presenters who received the highest ranking in their categories of
postdoctoral fellow, undergraduate
student, medical student, graduate student, and resident physician.
Outstanding Abstract Achievement
Award recipients receive a $500
honorarium plus annual meeting
travel reimbursement.
Postdoctoral Fellow
Léon Kautz, PhD
University of California, Los Angeles
Abstract #4
The Erythroid Factor Erythroferrone and Its Role in Iron Homeostasis
Today's Plenary Scientific Session
3:15 p.m., Hall F, Ernest N. Morial Convention Center
Dr. Kautz is also this year's Joanne Levy Memorial Award for Outstanding Achievement recipient and a Scholar Award winner. Read
more about his achievements in today's paper (see page B-22) and in
Monday's paper.
After multiple failures, single-agent
Undergraduate Student
Meredith Fay
Georgia Institute of Technology
and Emory University
Abstract #3459
White Blood Cell Mechanics Mediate Glucocorticoid- and Catecholamine-Induced Demargination
201. Granulocytes, Monocytes,
and Macrophages: Poster Session III
»» OAAA Page B-15
response
ADCETRIS® (brentuximab vedotin) injection for intravenous infusion
is indicated for the treatment of:
Important Safety
Information (continued)
* Hodgkin lymphoma (HL) after failure of autologous stem cell transplant (ASCT)1
* Progressive multifocal
leukoencephalopathy (PML):
JC virus infection resulting in PML
and death has been reported in
ADCETRIS® (brentuximab vedotin)-
treated patients. In addition to
ADCETRIS therapy, other possible
contributory factors include prior
therapies and underlying disease
that may cause immunosuppression.
Consider the diagnosis of PML in
any patient presenting with newonset signs and symptoms of central
nervous system abnormalities.
Evaluation of PML includes, but
is not limited to, consultation
with a neurologist, brain MRI, and
lumbar puncture or brain biopsy.
Hold ADCETRIS if PML is suspected
and discontinue ADCETRIS if PML
is confirmed.
* Stevens-Johnson syndrome (SJS):
SJS has been reported with
ADCETRIS. If SJS occurs, discontinue
ADCETRIS and administer
appropriate medical therapy.
* Embryo-fetal toxicity: Fetal harm can
occur. Advise pregnant women of the
potential hazard to the fetus.
* HL in patients who are not ASCT candidates after failure of at least 2 multiagent chemotherapy regimens1
Duration of response1,*
Rate of response1
HL: 73% objective response rate (ORR)
(95% CI: 65%-83%)
6.7 months ORR (4.0-14.8) 1.3 to 21.9
‡
32%
40%
20.5 months CR (12.0-NE )
complete remission (CR)
(95% CI: 23%-42%)
partial remission (PR)
(95% CI: 32%-49%)
3.5 months PR
†
(Range, months)
1.4 to 21.9‡ (Range, months)
(2.2-4.1) 1.3 to 18.7 (Range, months)
Median (95% CI)
N = 102, 15-77 years (median: 31 years)1
* Systemic anaplastic large cell lymphoma (sALCL) after failure of at least 1 multiagent chemotherapy regimen1
Rate of response1
Duration of response1,*
sALCL: 86% objective response rate (ORR)
(95% CI: 77%-95%)
57%
complete remission (CR)
(95% CI: 44%-70%)
29%
partial remission (PR)
(95% CI: 18%-41%)
N = 58, 14-76 years (median: 52 years)1
12.6 months ORR (5.7-NE ) 0.1 to 15.9
†
(Range, months)
‡
13.2 months CR (10.8-NE ) 0.7 to 15.9
†
2.1 months PR
‡
(Range, months)
(1.3-5.7) 0.1 to 15.8‡ (Range, months)
Median (95% CI)
The indications for ADCETRIS are based on response rate. There are no data available demonstrating improvement in patient-reported outcomes
or survival with ADCETRIS.1
UPDATED DOSING INFORMATION:
* Dose to disease progression or unacceptable toxicity1
* Administer only as an intravenous infusion over 30 minutes every 3 weeks1
* The recommended dose is 1.8 mg/kg1
* The dose for patients weighing greater than 100 kg should
be calculated based on a weight of 100 kg1
* The recommended starting dose is 1.2 mg/kg in patients
with hepatic impairment or severe renal impairment1
* Do not administer as an intravenous push or bolus1
Adverse Reactions:
ADCETRIS was studied as monotherapy
in 160 patients in two phase 2 trials.
Across both trials, the most common
adverse reactions (≥20%), regardless
of causality, were neutropenia,
peripheral sensory neuropathy, fatigue,
nausea, anemia, upper respiratory
tract infection, diarrhea, pyrexia, rash,
thrombocytopenia, cough and vomiting.
Drug Interactions:
Concomitant use of strong CYP3A4
inhibitors or inducers, or P-gp
inhibitors, has the potential to
affect the exposure to MMAE.
Use in Specific Populations:
MMAE exposure is increased in patients
with hepatic impairment and severe
renal impairment.
REFERENCE: 1. ADCETRIS [Prescribing Information].
Bothell, WA: Seattle Genetics, Inc; September 2013.
USP/BVP/2013/0036
*Calculated from the date of first response to the date
of progression or data cutoff date.
†
Not estimable.
‡
Follow-up was ongoing at the time of data submission.
Please see Brief Summary of full Prescribing Information,
including Boxed WARNING, on the last page of this ad.
10/30/13 1:34 PM
Table of Contents for the Digital Edition of ASH News Daily 2013 - Day 2
Table of Contents
ASH News Daily 2013 - Day 2
https://www.nxtbookmedia.com